Skip to content
Search

Latest Stories

Comedian Sue Perkins says ADHD is not an 'excuse' to avoid responsibility

She is well known for her role as a former co-host of 'The Great British Bake Off'

Sue Perkins

Sue Perkins has previously been praised for her openness about personal challenges

Getty

Television presenter and comedian Sue Perkins has spoken candidly about her experience of living with attention deficit hyperactivity disorder (ADHD), emphasising that she does not "weaponise" her diagnosis to excuse her behaviour.

Perkins, 55, is well known for her role as a former co-host of The Great British Bake Off, as well as for her current work on the BBC game show Chess Masters: Endgame. Speaking in an interview with Radio Times, she reflected on her relatively recent diagnosis of ADHD and the impact it has had on her understanding of herself.


“It was useful to have [the diagnosis]. I now understand why some things make me very upset and stressed. I understand why I lose everything, why I can’t prepare for things, why I don’t like repetition,” she said. However, Perkins was clear that she does not use her diagnosis as an excuse. “I live in a world where those things are expected, so it’s not about going, ‘I can’t and I won’t because I’ve got a certificate.’ I don’t weaponise it to make excuses for things that I do that aren’t optimal. I want to be the best version of myself.”

According to the NHS, adults with ADHD often show signs of inattentiveness, hyperactivity, and impulsiveness. This can include struggling to concentrate, being forgetful, finding it difficult to organise time effectively, feeling restless, and having a lot of energy. Individuals may also be very talkative, interrupt conversations, and make quick decisions without fully considering the consequences.

Perkins previously spoke about her diagnosis on social media. In 2023, she responded to a post by British songwriter and Gomez band member Tom Gray, who discussed his own journey towards an ADHD diagnosis. Gray wrote on X (formerly Twitter): “I’m creeping towards an ADHD diagnosis. Strongly advised to do it to help me but more likely help people who have relationships with me. Never realised before how object permanence is such a problem for me. Staying in touch rarely if ever occurs to me. I can only apologise.”

Perkins replied: “I have fully crept. Once I had the diagnosis, suddenly everything made sense – to me and those who love me. Wishing you well on the journey, Tom x.”

As she continues to navigate her condition, Perkins remains active professionally. Alongside her television presenting work, she is preparing to embark on a new stand-up comedy tour titled The Eternal Shame of Sue Perkins. The live tour is set to begin in January 2026 and marks her return to the stage with a solo performance.

Perkins also continues her collaboration with long-time comedy partner Mel Giedroyc. The pair co-host a podcast titled Mel & Sue: Should Know By Now, where they discuss a wide range of topics with their trademark humour and candidness.

Sue Perkins has previously been praised for her openness about personal challenges, including her health and private life. By speaking publicly about her ADHD diagnosis, she joins a growing number of public figures helping to raise awareness about adult ADHD, a condition often misunderstood and underdiagnosed.

Experts note that while ADHD is commonly associated with childhood, it often continues into adulthood and can present significant challenges. Early diagnosis and management strategies can help individuals better understand and navigate the effects on daily life.

Perkins’ decision to share her experience reflects a broader shift towards more open conversations about mental health and neurodiversity. Her message remains clear: she seeks to live positively with the condition and continue striving for personal growth, rather than using her diagnosis as a limitation.

More For You

heatwave

The Met Office and UK Health Security Agency (UKHSA) have issued amber heat-health alerts

Getty Images

Doctors warn of hidden signs of heat stroke as UK issues amber alerts

Key points

  • Amber heat-health alerts issued as temperatures approach 35°C in parts of the UK.
  • Early signs of heat stroke include confusion, slurred speech, and dizziness.
  • Heat exhaustion can develop into heat stroke if not treated within 30 minutes.
  • At-risk groups include the elderly, young children, and those with health conditions.
  • NHS and health experts urge people to stay hydrated, cool, and avoid midday sun.

Medical experts are urging the public to remain alert for the early signs of heat stroke, as temperatures across parts of England are expected to reach up to 35°C. The Met Office and UK Health Security Agency (UKHSA) have issued amber heat-health alerts, warning that extreme heat can have serious health impacts. Doctors stress that symptoms can begin subtly, making early intervention crucial.

Heat alerts across multiple regions

Amber-level warnings are in effect for the West Midlands, East Midlands, Yorkshire and the Humber, South East, South West, London, and the East of England.

Keep ReadingShow less
weight loss injections UK

The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow

iStock

Hundreds report pancreas issues linked to weight loss injections as UK launches safety study

Key points

  • Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
  • Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
  • Health officials are investigating possible genetic causes behind the side-effects
  • Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
  • Adverse drug reactions cost the NHS an estimated £2.2bn annually

Health watchdog investigates spike in serious side-effects from GLP-1 drugs

UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.

The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.

Keep ReadingShow less
Weight Loss Drug

Health officials expect the rollout to benefit around 220,000 adults over the next 3 years

iStock

NHS GPs to prescribe Mounjaro in nationwide obesity treatment plan

Key points

  • NHS GPs in England can now prescribe Mounjaro (tirzepatide) for weight loss
  • The programme aims to support 220,000 people over three years
  • Eligible patients must have a BMI over 40 and at least four obesity-related health issues
  • GP leaders raise concerns over increased workload
  • Pharmacists urge a broader weight management approach

NHS expands obesity treatment with Mounjaro

The NHS in England is set to begin prescribing Mounjaro, a weight loss injection, through GP surgeries starting Monday. The move marks the first time family doctors will be authorised to directly prescribe the anti-obesity drug tirzepatide as part of a wider national health initiative.

Health officials expect the rollout to benefit around 220,000 adults over the next three years. The drug will be made available to those with a body mass index (BMI) above 40 who also suffer from at least four other obesity-related conditions, such as type 2 diabetes, high blood pressure, or sleep apnoea.

Keep ReadingShow less
UK heatwave deaths

Around 85% of the projected deaths are likely to involve people over the age of 65

iStock

Scientists warn current UK heatwave may cause nearly 600 early deaths

Almost 600 premature deaths are expected to occur during the ongoing heatwave affecting England and Wales, according to a new rapid analysis by leading scientists. The majority of fatalities are projected among older adults, with London and the West Midlands likely to be the worst-affected areas.

Climate change driving deadly temperatures

Researchers say the extreme temperatures, which have reached 32°C in parts of south-east England, would have been nearly impossible without the influence of human-caused climate change. Pollution from burning fossil fuels has raised the likelihood of such heatwaves by around 100 times, experts say.

Keep ReadingShow less
Amycretin

'The Lancet' and presentations at the American Diabetes Association’s 2025

iStock

New weight-loss pill Amycretin shows greater impact than jabs, study finds

A new weight-loss drug, amycretin, has delivered the most significant results yet for appetite-suppressing GLP-1 medications, according to two newly published studies in The Lancet and presentations at the American Diabetes Association’s 2025 Scientific Sessions in Chicago.

Record weight loss from Amycretin injections

Researchers found that participants receiving high-dose weekly injections of amycretin lost 24.3 per cent of their body weight over 36 weeks. This outcome surpasses the results seen in longer trials involving other GLP-1 drugs such as tirzepatide (sold as Mounjaro), which previously led the field with an average weight loss of 20 per cent over 72 weeks.

Keep ReadingShow less